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Background: Accumulating evidence has suggested the importance of glutamate signaling in cancer growth, yet
the signaling pathway has not been fully elucidated. N-methyl-D-aspartic acid (NMDA) receptor activates
intracellular signaling pathways such as the extracellular-signal-regulated kinase (ERK) and forkhead box, class O
(FOXO). Suppression of lung carcinoma growth by NMDA receptor antagonists via the ERK pathway has been
reported. However, series of evidences suggested the importance of FOXO pathways for the regulation of normal
and cancer cell growth. In the liver, FOXO1 play important roles for the cell proliferation such as hepatic stellate
cells as well as liver metabolism. Our aim was to investigate the involvement of the FOXO pathway and the target
genes in the growth inhibitory effects of NMDA receptor antagonist MK-801 in human hepatocellular carcinoma.
Methods: Expression of NMDAR1 in cancer cell lines from different tissues was examined by Western blot. NMDA
receptor subunits in HepG2, HuH-7, and HLF were examined by reverse transcriptase polymerase chain reaction
(RT-PCR), and growth inhibition by MK-801 and NBQX was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assay. The effects of MK-801 on the cell cycle were examined by flow
cytometry and Western blot analysis. Expression of thioredoxin-interacting protein (TXNIP) and p27 was determined
by real-time PCR and Western blotting. Activation of the FOXO pathway and TXNIP induction were examined by
Western blotting, fluorescence microscopy, Chromatin immunoprecipitation (ChIP) assay, and reporter gene assay.
The effects of TXNIP on growth inhibition were examined using the gene silencing technique.
Results: NMDA receptor subunits were expressed in all cell lines examined, and MK-801, but not NBQX, inhibited
cell growth of hepatocellular carcinomas. Cell cycle analysis showed that MK-801 induced G1 cell cycle arrest by
down-regulating cyclin D1 and up-regulating p27. MK-801 dephosphorylated Thr24 in FOXO1 and induced its
nuclear translocation, thus increasing transcription of TXNIP, a tumor suppressor gene. Knock-down of TXNIP
ameliorated the growth inhibitory effects of MK-801.
Conclusions: Our results indicate that functional NMDA receptors are expressed in hepatocellular carcinomas and
that the FOXO pathway is involved in the growth inhibitory effects of MK-801. This mechanism could be common
in hepatocellular carcinomas examined, but other mechanisms such as ERK pathway could exist in other cancer
cells as reported in lung carcinoma cells. Altered expression levels of FOXO target genes including cyclin D1 and
p27 may contribute to the inhibition of G1/S cell cycle transition. Induction of the tumor suppressor gene TXNIP
plays an important role in the growth inhibition by MK-801. Our report provides new evidence that FOXO-TXNIP
pathway play a role in the inhibition of the hepatocellular carcinoma growth by MK-801.
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Glutamate signaling is important for excitatory synaptic
transmission in the central nervous system (CNS) and play
a critical role in synaptic plasticity, a cellular mechanism
for learning and memory [1,2]. In addition, glutamate re-
ceptors are expressed in non-neuronal cells throughout
the body, including bone, skin, lung, liver, heart and kid-
ney, and play distinct physiological roles in these tissues
[3,4]. Interestingly, glutamate signaling is also involved in
diseases such as cancer and neurological disorders [5-7].
In cancer cells, glutamate signaling pathways are dys-
regulated and glutamate is released from cancer cells,
stimulating cell growth [8,9]. In pancreatic cancer, glutam-
ate stimulates cell invasion and migration [10].
Glutamate receptors are divided into two major groups:
ionotropic and metabotropic receptors [11,12]. The former
group is further classified into three members based on
their agonists: N-methyl-D-aspartic acid (NMDA), α-amino
-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) and
kainate receptors. Of these, the NMDA receptor forms a
heterotetramer between the NR1 and NR2 subunits, in-
cluding NR2A, NR2B, NR2C and NR2D, or NR3 subunits,
such as NR3A and NR3B [13]. The NR1 subunit is neces-
sary for calcium conductivity through the channel and the
NR2 and NR3 subunits determine electrophysiological and
pharmacological properties of the receptors. The different
expression and distribution patterns of NR2 and NR3 sub-
units are responsible for the distinct functional properties
of these receptors. In the brain, NMDA receptors are in-
volved in the promotion of neuronal cell death or survival
in addition to signal transduction via Ca2+ entry through
NMDA receptors [14]. Synaptic NMDA receptor activity
suppresses the induction of cell death-related genes such as
Puma, Apaf-1 and FOXO [14]. Suppression of FOXO
down-regulates target genes, including Bim, FasL and
TXNIP, a tumor suppressor gene [15,16], whereas over-
expression of FOXO1 enhances TXNIP promoter activity
[17]. TXNIP was originally cloned as a vitamin D3 up-
regulated protein (VDUP1) after 1, 25-dihydroxyvitamin
D3 treatment of HL-60 cells [18]. Its expression is down-
regulated in many tumor cells [19,20] and overexpression
of TXNIP inhibits cancer cell growth [21].
NMDA receptors are expressed in many cancer cell
lines and tumors, including glioma [22], oral squamous
cell carcinoma [23], gastric cancer [24], prostate cancer
[25] and osteosarcoma [26]. The expression pattern of
the receptors differs between these cells [7]. NMDA re-
ceptors may play an important role in the growth of can-
cer cells, as there is some evidence that administration
of glutamate antagonists inhibits cancer cell growth de-
rived from brain, thyroid, colon, breast and lung tumors
[27,28]. Although knowledge of the detailed mechanisms
is limited, growth suppression of lung adenocarcinoma
by the NMDA antagonist MK-801 via inhibition of theERK pathway and induction of the tumor suppressor
protein p21 and p53 has been reported [28].
As NMDA receptor signaling regulates cell death
pathways such as FOXO in the CNS, we assumed that
this pathway might be involved in the NMDA receptor
signaling in cancer cells. In fact, FOXO pathway is in-
volved in the regulation of cancer cell growth and FOXO
is known as a tumor suppressor [29,30]. In the liver,
FOXO pathway is important for cell proliferation [31]
and the metabolism [32]. Therefore, we focused on the
NMDA signaling and FOXO pathway in hepatocellular
carcinomas. In this study, we confirmed the expression
of NMDA receptors in HepG2, HuH-7, and HLF human
hepatocellular cell lines. MK-801 suppressed the growth
of these cells via G1 cell cycle arrest. Activation of the
FOXO pathway and induction of TXNIP are involved in
growth suppression by MK-801.This mechanism via the
FOXO pathway is different from the previous report de-
scribing the importance of ERK pathway in the lung can-
cer treated with MK-801[28].
Methods
Materials
MK-801, NBQX (2,3-Dioxo-6-nitro-1,2,3,4- tetrahydro-
benzo[f]quinoxaline-7-sulfonamide), RNase A, DMEM
and MEM alpha were purchased from Sigma (St. Louis,
MO). 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetra-
zolum bromide (MTT) and propidium iodide were pur-
chased from Wako (Tokyo, Japan). Fetal bovine serum
(FBS) was purchased from MBL (Tokyo, Japan) and 1%
penicillin-streptomycin was obtained from GE Health-
care (Chalfont, St. Giles, England).
Cell culture
Human hepatocellular carcinoma cell lines, HepG2 and
HuH-7 were purchased from Riken Cell Bank (Tsukuba,
Japan) and HLF cell line was purchased from JCRB Cell
Bank (Osaka, Japan). Human colon colorectal carcinoma
cell line, HCT-116 was purchased from DS Pharma Bio-
medical Co. Ltd (Osaka, Japan). Human neuroblastoma cell
line, SH-SY5Y was obtained from ATCC (Manassas, VA).
These cells were maintained in DMEM supplemented with
10% (v/v) FBS and 1% penicillin-streptomycin at 37°C
under a humidified atmosphere of 5% CO2.
Cell viability assay
Cells were seeded into 96-well plates with 3 to 5 × 103
cells/well in 0.1 ml of medium and cultured for 24 h.
Various concentrations of MK-801 and NBQX were
added to the culture medium and cells were further cul-
tured. MTT solution (5 mg/ml in PBS) was added to
each well and plates were incubated for an additional
4 h at 37°C. To solubilize the formazan crystal formed in
viable cells, dimethylformamide-20% sodium dodecyl
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cubation on a shaker at 37°C. Absorbance was measured
on a microplate reader at 595 nm.
RT-PCR and quantitative real-time PCR
In accordance with the manufacturer’s protocol, total RNA
was purified from cultured cells using an RNAeasy mini
prep kit (Qiagen, Hilden, Germany) and cDNA was synthe-
sized using an Omniscript reverse transcriptase kit (Qiagen)
with random hexamers. For RT-PCR analysis, sequences of
the human NMDA receptor subunits were obtained from
GENBANK and PCR primers were designed (Table 1). PCR
was performed with these primers at 95°C for 3 min,
followed by 40 cycles at 95°C for 10 s, 65°C for 30 s, and
72°C for 30 s with PCR Thermal Cycler Dice (Takara, Otsu,
Japan). Amplified products were separated on 1.5% agarose
gel, and images were obtained. PCR products were also















































Sequences of the human NMDA receptor subunits were obtained from
GENBANK, and PCR primers were designed.(Toyobo, Tokyo, Japan) and sequences were confirmed
using an ABI 3700 sequencer (Applied Biosystems, Foster
City, CA). Real-time quantitative PCR was carried out using
Taqman gene expression assay primers and a 7300 real-
time PCR system (Applied Biosystems). The assay ID
of Taqman probe is Hs00197750_m1 for TXNIP and
Hs99999903_01 for β-actin. Each reaction was performed
in duplicate. The β-actin gene was used for normalization
across assays and runs, and the threshold value (Ct) for
each sample was used to determine gene expression levels.
Cell cycle analysis
Cells were cultured in 10-cm dishes with or without
250 μM of MK-801, and were harvested after 72 h by
trypsinization (0.25% trypsin / 1 mM EDTA), washed twice
with ice-cold PBS and fixed in 1 ml of 70% ethanol (1 × 106
cells/sample) for 2 h at 4°C. Cells were washed twice with
ice-cold PBS and incubated in 1 ml PBS containing 50 μg
propidium iodide and 200 μg RNase A for 30 min at 37°C
in the dark. Flow cytometric analysis was performed with
FACSEpics XL flow cytometer (Beckman Coulter, Fullerton,
CA). The effects of MK-801 on cell cycle were determined
by changes in the percentage cell distribution at each phase
of the cell cycle, and were analyzed using System II soft-
ware (Beckman Coulter).
Western blot analysis
Cells were washed with PBS and scraped into lysis buffer
(50 mM Tris–HCl pH 7.5, 0.5% Triton-X100, 0.5%
Tween20) containing protease inhibitors (Sigma), and
were sonicated. Samples were centrifuged for 10 min at
15,000 rpm at 4°C and the supernatants were collected.
Proteins were separated on SDS-PAGE gels, transferred
to nitrocellulose membranes and blocked with 5% (w/v)
non-fat dried milk in TTBS, followed by incubation with
anti-cyclin D1 (MBL), anti-cyclin E (MBL), anti-cyclin-
dependent kinase (CDK) 2 (Santa Cruz Biotechnology,
Santa Cruz, CA), anti-CDK4 (MBL), anti-p53 (Santa Cruz
Biotechnology), anti-p27 (Cell Signaling Technologies,
Beverly, MA), anti-p21 (Cell Signaling Technologies), anti-
TXNIP (Santa Cruz Biotechnology), anti-phospho-FOXO1/
FOXO3a (Thr24/Thr32), anti-NMDAR1 (Millipore,
Billerica, MA) and anti-FOXO1 (Cell Signaling Techno-
logies) in Can Get Signal Immunoreaction Enhancer
Solution (TOYOBO, Tokyo Japan), or with anti-β-actin
antibody (Sigma) in 5% (w/v) non-fat dried milk in TTBS.
Membranes were washed and probed with horseradish
peroxidase (HRP)-conjugated anti-rabbit or anti-mouse IgG
(GEHealthcare), and signals were detected using Immobilon
WesternchemiluminescentHRPsubstrate(Millipore).
Fluorescence microscopy
The coding region of FOXO1 was cloned into pAcGFP-
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Figure 1 (See legend on next page.)
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Figure 1 MK801 inhibited growth of hepatocellular carcinoma cells. A: Cell lysates prepared from hepatocellular carcinoma (HepG2, HuH-7,
and HLF), colon colorectal carcinoma (HCT-116), and neuroblastoma (SH-SY5Y) were separated on 12.5% SDS-PAGE and western blot analysis was
performed with anti-NMDAR1 or anti-β-actin antibody. B: Total RNA was purified from cultured cells and cDNA was synthesized with random
hexamers. PCR was performed with NMDAR subtype or β-actin specific primers Amplified products were separated on 1.5% agarose gels. C: Cells
were seeded into 96-well plates and different concentrations of MK-801 or NBQX were added to culture medium for 24 h. Cell viability was
measured by MTT assay. Each bar represents the mean ± SD of three replicates. D: Various concentrations of MK-801 were added to the medium
and cells were cultured for 72 h. Cell viability was measured by MTT assay. Each point represents the mean ± SD of three replicates.
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transfected using FuGENE HD transfection reagent
(Roche, Indianapolis, IN) in accordance with the manu-
facturer’s protocol. After 24 h, medium was replaced
with PBS and the temperature was kept at 37°C in a heat
chamber. GFP-tagged FOXO1 protein was visualized
with Olympus LX71 microscope (Olympus, Tokyo,
Japan) in the presence or absence of MK-801.
Reporter gene assay
The promoter region of human TXNIP containing a
conserved FOXO binding site (between −478 and −260
nucleotides from the start of protein coding region) was
obtained by PCR from human genomic DNA and
subcloned into the PGL4.6 reporter plasmid (Promega,
Madison, WI). Mutation construct with a destroyed
FOXO consensus sequence (FOXO-Mut) was created by
PCR using the PrimeSTAR Mutagenesis Prime Kit
(Takara). HepG2 (3 × 104 cells/well) cells were seeded into
24-well plates and reporter plasmid (500 ng/well) was co-
transfected with pGL4.74 control reporter plasmid (50 ng/
well) using FuGENE HD transfection reagent in accord-
ance with the manufacturer’s protocol. After 24 h of MK-
801 treatment, cells were lysed and luciferase activity was
measured using the Dual-Glo Luciferase Assay System
(Promega) with Luminoskan (Labosystems, Tokyo Japan).
Variations in transfection efficiency between samples were
normalized against the luminescence of a control reporter.
ChIP (chromatin immunoprecipitation) assay
The ChIP assay was performed using a ChIP-IT High Sen-
sitivity Kit (Active Motif, Carlsbad, CA) according to the
manufacturer’s instructions. Briefly, 6 × 106 cells were
fixed and shared. ChIP reactions were performed on 5 μg
of prepared chromatin using 5 μl of anti-phospho-FOXO
antibody. The immune complexes were then collected
with the addition of Protein G agarose beads, followed by
several washes with appropriate buffers, according to the
manufacturer’s instructions. Chromatin-associated proteins
were digested with proteinase K (10 mg/ml), and the
immunoprecipitated DNA was recovered by spin columns.
PCR was performed using input or immunoprecipitated
DNA. The primers used for ChIP were as follows: 5′-
CACGCGCCACAGCGATCTCACTGA-3′ (−472 to −449,sense) and 5′-AGATCCGATCTCCACAAGCACTCC-3′
(−284 to −261, antisense). The PCR product was separated
in 1.5% agarose gel.
Gene knock-down by small interfering RNA (siRNA)
HepG2 cells (5 × 104 cells/well) were cultured in a 96-
well plate. For the knock-down experiment, 5 nM
TXNIP siRNA (siRNA1: 5′-UGCUCGAAUUGACA-
GAAAATT-3′, siRNA2: 5′-GUGGAGGUGUGUGAAG-
UUATT-3′, Cosmo Bio Co. Ltd., Tokyo, Japan) or negative
control siRNA (Qiagen) was transfected using the Hiperfect
transfection reagent (Qiagen) in accordance with the
manufacturer’s protocol. After 24 h, MK-801 (125 or
250 μM) was added to the medium and cells were further
incubated for 48 h. Cell viability was examined using the
MTT method.
Statistical analysis
Data are presented as means ± SD of at least three inde-
pendent experiments. Differences between groups were
analyzed by one-way analysis of variance with Bonferroni
post-hoc analysis or unpaired t-test.
Results
Expression of NMDA receptor subunits in hepatocellular
carcinoma cell lines
First, we compared the expression of NMDAR1 receptor
by western blot analysis using cells lines from different
origins including SH-SY5Y (neuroblastoma), HCT-116
(colon colorectal carcinoma), and three hepatocarci-
nomas (HepG2, HuH-7, and HLF). We detected a sub-
stantial amount of NMDAR1 expression in all cell lines
examined (Figure 1A). This result is similar to the previ-
ous report describing the NMDAR1 expression in per-
ipheral tissues including heart, kidney, liver, and spleen
[33]. Next, we analyzed the expression of each receptor
subunit in HuH-7, HepG2, and HLF cell lines. Specific
primers for NMDA receptor subunits were designed
(Table 1) and RT-PCR was carried out. In HepG2 and
HuH-7 cell lines, expression of NR1, NR2 (R2A, R2B,
R2C and R2D) and NR3B subunits was confirmed,
whereas NR3A expression was not detected (Figure 1B).
We could not detect NR2B subunit in HLF cells, but












































































































































Figure 2 (See legend on next page.)
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Figure 2 Cell cycle analyses by flow cytometry and Western blotting. A: Hepatocellular carcinoma cells were cultured in 10-cm dishes with
or without 250 μM MK-801 and were harvested after 72 h by trypsinization and fixed in 70% ethanol. Cells were incubated in 1ml PBS containing
50 μg propidium iodide and 200 μg RNase A. Flow cytometric analysis was performed with a FACSEpics XL flow cytometer. Each bar represents
the mean ± SD of three replicates. B: Cell lysates from control or MK-801 (250 μM) treated cells were prepared and proteins were separated on
SDS-PAGE gels and transferred onto nitrocellulose membranes. Western blot analysis was performed with indicated antibodies.
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HuH-7, and HLF cell proliferation
As these hepatocellular carcinoma cell lines expressed
NMDA receptor subunits, the effects of the NMDA antag-
onist, MK-801 on proliferation was examined and com-
pared to that of the non-NMDA receptor antagonist,
NBQX. Increasing concentrations of these antagonists were
applied, and cell viability was examined by MTT assay after
24 h (Figure 1C). MK-801 inhibited the growth of these
cells in a dose-dependent manner. Treatment with MK-801
(500 μM) decreased cell viability to 31.6% ± 0.9% (HepG2),
40.9% ± 5.8% (HuH-7), and 56.6% ± 1.5% (HLF) (n = 3
each). These results indicated that the NMDA receptors in
these cell lines were functional and may regulate growth. In
contrast, NBQX showed no clear effects on the prolifera-
tion of either cell lines, although a weak inhibitory effect
was observed in HuH-7 cells. Cell viability was examined
up to 72 h after drug treatment (Figure 1D). After 72 h,
growth suppression with 500 μM MK-801 reached 9.0% ±
1.4% with HepG2, 15.5% ± 2.2% with HuH-7 cells, and
19.3% ± 3.8% with HLF cells (n = 3 each).
MK-801 inhibits G1/S transition of the cell cycle
In order to clarify the mechanism of MK-801-induced
inhibition of cell growth, we analyzed cell cycle progres-
sion in both cell lines by flow cytometry (Figure 2A).
When compared with controls, MK-801 increased the
percentage of HepG2 cells in G1 phase (8.2% ± 0.1%)
and decreased that in G2/M and S phases (−5.4% ± 2.0%
and −2.8% ± 0.1%, respectively). In HuH-7 cells, MK-801
also increased the percentage in G1 phase (6.8% ± 0.6%)
and decreased that in G2/M and S phases (−0.6% ± 0.7%
and −6.3% ± 0.2%, respectively). In HLF cells, MK-801 in-
creased the percentage of cells in G1 phase (6.1% ± 0.2%)
and decreased that in G2/M and S phases (−5.4% ± 2.0%
and −2.3% ± 0.1%, respectively). These results indicate that
MK-801 inhibits G1/S cell cycle transition. The expression
level of cell cycle-regulating proteins was then examined
by Western blot analysis (Figure 2B). In these cells, down-
regulation of cyclin D1, p53 and p21 was observed. In
addition, expression of cyclin E, CDK2 and CDK4 was
down-regulated in HuH-7 cells. Interestingly, expression
of p27 was up-regulated in all cell lines.
MK-801 induces TXNIP expression
As NMDA receptors regulate cell death via several path-
ways, including FOXO [14], we examined the effects ofMK-801 and NBQX on expression of the FOXO target
gene TXNIP by real-time PCR (Figure 3A). After 12 h,
MK-801 (250 μM) induced significant TXNIP expression
(453.7% ± 17.5% with HepG2 and 496.2% ± 23.8% with
HuH-7 cells). In contrast, NBQX showed no clear effect
on TXNIP expression. The induction of TXNIP mRNA
reached 900% after 48 h of MK-801 (250 μM) treatment
(Figure 3B). TXNIP is known to induce cell cycle arrest
by stabilizing p27 protein via inhibition of JAB1 [34].
Therefore, we examined the time-course changes of p27
mRNA and protein levels. After 48 h, protein levels
of p27 were clearly elevated by MK-801 treatment
(Figure 3C). In contrast, induction of p27 mRNA was
slower and reached 251.9% ± 21.4% after 72 h (Figure 3B).
Transcriptional activity of FOXO1 is regulated by the
phosphorylation state of Thr24, Ser256 and Ser319 [35].
Western blot analysis showed that MK-801 treatment of
HepG2 cells rapidly (within 20 min) dephosphorylated
phospho-FOXO1. The molecular weight of the dephos-
phorylated band corresponded to Thr24 of FOXO1
(Figure 3D). The dephosphorylation of FOXO1 induces
the nuclear translocation and increases the expression of
FOXO1 target genes [35]. MK-801 treatment of HepG2
cells enhanced the nuclear localization of FOXO1
(Figure 3E).
Regulation of TXNIP expression by FOXO and role of
TXNIP in growth inhibition
The promoter region of TXNIP contains a conserved
consensus sequence, ′GTAAACAA′, of the FOXO bind-
ing site that regulates TXNIP transcription [17]. To
analyze the effects of MK-801 on TXNIP expression,
we constructed a luciferase reporter gene plasmid by
subcloning the promoter region of human TXNIP (wild
type) or FOXO-Mut by destroying the FOXO binding
site (Figure 4A). These plasmids were transfected into
HepG2, and the effects of MK-801 on TXNIP promoter
activity were examined (Figure 4B). MK-801 increased
the promoter activity when the wild-type promoter
region was transfected, but failed to activate the FOXO-
Mut promoter.
To confirm the binding of FOXO to TXNIP promoter,
we performed ChIP assay on HepG2 cells treated with
or without MK-801 (Figure 4C). When cells were treated
with MK-801, primers flanking a FOXO consensus bind-
ing site specifically amplified DNA sequences immuno-




































































Figure 3 Activation of FOXO pathway and TXNIP induction. A: HepG2 and HuH-7 cells were treated with 250 μM MK-801 or NBQX for 12 h.
cDNA was synthesized and real-time quantitative PCR was carried out using Taqman gene expression assay primers. Each reaction was performed
in duplicate. The β-actin gene was used to normalize across assays and runs, and the threshold value (Ct) for each sample was used to determine
gene expression levels. Each bar represents the mean ± SD of at least three replicates. B: HepG2 cells were treated with 250 μM MK-801 and
expression of TXNIP and p27 was measured by real-time quantitative PCR for 72 h. Each bar represents the mean ± SD of at least three replicates.
C: HepG2 cells were treated with 250 μM MK-801 for 0 to 96 h and Western blot analysis was performed using indicated antibodies. D: HepG2
cells were treated with 250 μM MK-801 for 0 to 60 min and Western blot analysis was carried out using indicated antibodies. The molecular
weight of dephosphorylated band corresponded to Thr24 of FOXO1 E: FOXO1-pAcGFP-N1 plasmid was transfected to HepG2 cells and treated
with or without 250 μM of MK-801. Nuclear translocation of FOXO1-GFP protein was observed with Olympus LX71 microscope.























































































































Figure 4 Regulation of TXNIP expression by FOXO and role of TXNIP in growth inhibition. A: The promoter region of human TXNIP
containing the FOXO binding site (between −478 and −260 nucleotides from the start of the protein coding region) is shown. FOXO-Mut: The
consensus sequence of FOXO binding site was destroyed by two nucleotide mutations. B: Reporter gene plasmid containing the wild-type or
FOXO-Mut promoter fragment and pGL4.74 control plasmid was co-transfected into HepG2 cells. After 24 h of MK-801 (250 μM) treatment,
luciferase activity was measured. Each bar represents mean ± SD of three replicates. *P < 0.05. C: HepG2 cells were treated with or without MK-
801 (250 μM). ChIP reaction was performed on 5ug of prepared chromatin using anti-phospho-FOXO antibody. PCR was carried out with input or
immunoprecipitaed DNA using specific primers flanking the FOXO binding site in the TXNIP promoter region. D: The gene knock-down efficiency
of two TXNIP siRNAs as well as negative control on HepG2 cells was examined by Western blot. TXNIP/β-actin ratio was calculated from the
density of each band. E: HepG2 cells were cultured on a 96-well plate and 5 nM of TXNIP or negative control siRNA was transfected. After 48 h of
MK-801 (125 or 250 μM) treatment, cell viability was examined by the MTT assay. Data were statistically analyzed by one-way analysis of variance
and Bonferroni post-test. *P < 0.05.
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which supports the result of the increase of luciferase activ-
ity in Figure 4B. Next, we examined the effects of TXNIP
on MK-801-induced cancer cell growth inhibition. We
tested two different TXNIP siRNAs to eliminate the possi-
bility of off-target effects. The western blot showed that
both TXNIP siRNAs effectively knocked down the TXNIP
expression (Figure 4D). These TXNIP or negative control
siRNA were transfected into HepG2 cells and the effects of
MK-801 were analyzed by the MTT method. TXNIP
siRNAs significantly attenuated the effects of cell growth
inhibition by MK-801 (P < 0.05) (Figure 4E).
Discussion
Our study demonstrated that the NMDA receptor an-
tagonist MK-801 inhibited growth of HepG2, HuH-7,
and HLF human hepatocellular carcinomas, and that the
effects were induced by the functional expression of
NMDA receptors in these cancer cells. The expression
pattern of NMDA receptor subtypes was similar between
HepG2 and HuH-7 cell lines. HLF cells lack NR2B, but
express NR3A subtypes. MK-801 inhibited the growth of
these cells in a dose dependent manner. In contrast,
NBQX, an AMPA receptor antagonist, showed no effect
on HepG2 cell growth, whereas weak inhibition was ob-
served in HuH-7 cells. Although the involvement of
AMPA receptors in cancer cell growth in glioblastoma,
colon and lung carcinoma has been reported [28,36], the
expression of AMPA receptors in liver or hepatocellular
carcinoma is unknown. Further study of AMPA receptor
signaling in hepatocellular carcinoma could be useful in
interpreting the results of NBQX.
The antiproliferative effects of MK-801 arise from cell
cycle arrest caused by modulation of cell cycle-
regulating gene expression. A previous study using lung
carcinoma A549 cells demonstrated that MK-801 sup-
presses cancer cell growth by down-regulating cyclin D1
and up-regulating p53 and p21 expression [28]. Cyclin
D1 is essential for cell cycle progression in G1 [37] and
p21 is important for p53-mediated G1 arrest in human
cancer cells [38]. Silencing p21 ameliorates the
antiproliferative effects of MK-801, thus suggesting that
p21 is a key regulator of cell cycle arrest by MK-801.
The expression levels of these cell cycle-regulating genes
could be modulated by inhibiting the ERK pathway [28].
Interestingly, in the HepG2, HuH-7, and HLF cell lines,
p53 and p21 were down-regulated and p27 was up-
regulated by MK-801. The level of p27 controls G1 cell
cycle progression and increased levels of p27 induce cell
cycle arrest at the G1 phase [39]. Up-regulation of p27
by MK-801 may contribute to G1 cell cycle arrest in
these cells.
NMDA receptor signaling is linked to the FOXO path-
way as well as to the ERK pathway [14]. FOXO1 is amember of forkhead family of transcription factors and
regulates the expression of a number of genes that play
critical roles in cell cycle and apoptosis [40]. In addition,
FOXO plays a tumor suppressor role in various cancers
[29,30]. FOXO induces G1 cell cycle arrest by inducing
p27 [41,42] and suppressing cyclin D1 expression [43].
TXNIP is identified as another FOXO target gene [44]
and MK-801 increases TXNIP promoter activity [28].
Transcriptional activity of FOXO1 is regulated by the
phosphorylation state of Thr24, Ser256 and Ser319 and
phosphorylation at these sites suppress transactivation
and promotes the redistribution of FOXO1 outside the
nucleus [35]. Activation of FOXO1 by Thr24 dephos-
phorylation may induce down-regulation of cyclin D1
and up-regulation of p27. In addition, transcriptional ac-
tivation of the FOXO target gene TXNIP acts as a tumor
suppressor. TXNIP stabilizes p27 protein by inhibiting
its degradation via JAB1 [34] and induces G1 cell cycle
arrest [21]. This may explain the differences in transcript
and protein levels of p27 in the time course study. Our
study indicates that the TXNIP-FOXO axis contributes
to cell cycle arrest and is important for MK-801-medi-
ated hepatocellular carcinoma growth inhibition. This
mechanism could be common in hepatocellular carcin-
omas examined, but other mechanisms such as ERK
pathway could exist in other cancer cells as reported in
lung carcinoma cells [28].
Conclusions
In conclusion, this study provides insight into the role of
the FOXO signaling pathway on growth inhibition by
the NMDA receptor antagonist MK-801 in hepatocellu-
lar carcinoma. In addition, our data indicate that FOXO
activates transcription of the tumor suppressor gene
TXNIP, which contributes to the growth inhibitory ef-
fects of MK-801. Our report provides new evidence that
FOXO-TXNIP pathway play a role in the inhibition of
the hepatocellular carcinoma growth by MK-801. Future
research should therefore consider members of this
pathway as potential targets for the treatment of hepato-
cellular carcinoma through NMDA receptor signaling.
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